Samy Y. Lamouille, Ph.D.
“Some cancer stem cells are resistant to chemotherapy. If even a small population of these cells are left behind after treatment, then they can rapidly seed the growth of new tumors. By targeting the proteins that are really important for invasion, we may be able to inhibit metastasis in aggressive cancers."
Developing new cancer therapies
If we target cancer stem cells, can we prevent cancer recurrence?
Dr. Lamouille's lab studies how cancer cells communicate and is developing novel therapeutic strategies to target these communication mechanisms to prevent metastases in human cancer progression. In particular, the lab specializes in studying epithelial-mesenchymal transition (EMT) - a process that enables cancer cells to undergo a complete reprogramming at the trasncription, translation, and post-translation levels, leading cancer cells to acquire the invasive characteristics that promote cell proliferation and metastases in new tissues.
The Lamouille Lab analyzes the channel-dependent and -independent roles of connexin proteins during EMT and in cancer stem cells. Transforming Growth Factor-β (TGF-β) is a potent inducer of EMT and regulator of cancer stemness through Smad and non-Smad signaling, and crosstalk with other pathways such as Notch and Wnt. Dr. Lamouille studies how these signaling pathways modulate connexin localization and function in cancer cells that undergo EMT, and in cancer stem cells. The lab is developing novel therapeutic strategies using mimetic peptides to specifically disrupt protein-protein interactions that enhance the tumorigenic characteristics of cancer cells. To carry these discoveries forward and pursue clinical trials, Dr. Lamouille co-founded Acomhal Research Inc. in partnership with Dr. Rob Gourdie.
- Assistant Professor, Fralin Biomedical Research Institute at VTC
- Research Assistant Professor, Department of Biological Sciences, College of Science
- Assistant Professor, Department of Basic Science Education, School of Medicine
Katsuno Y, Qin J, Oses-Prieto J, Wang H, Jackson-Weaver O, Zhang T, Lamouille S, Wu J, Burlingame A, Xu J, Derynck R. (2018). Arginine methylation of SMAD7 by PRMT1 in TGF-β-induced epithelial-mesenchymal transition and epithelial stem-cell generation. Journal of Biological Chemistry 293: 13059-72.
James CC, Zeitz MJ, Calhoun PJ, Lamouille S, Smyth JW. (2018). Altered translation initiation of Gja1 limits gap junction formation during epithelial-mesenchymal transition. Molecular Biology of the Cell 29(7): 773-880.
Murphy SF, Varghese RT, Lamouille S, Guo S, Pridham KJ, Kanabur P, Osimani AM, Sharma S, Jourdan J, Rodgers CM, Simonds GR, Gourdie RG, Sheng Z. (2016). Connexin 43 Inhibition Sensitizes Chemoresistant Glioblastoma Cells to Temozolomide. Cancer Research 76(1): 139-49.
- Sarcotein Diagnostics
Principal Scientist - University of California, San Francisco
Research Assistant
- University of Grenoble: Ph.D. Molecular and Cell Biology
- University of Grenoble: B.S., Biochemistry
- University of California, San Francisco: Postdoctoral Fellowship
- American Heart Association Scientist Development Award
-
Article Item
From Ghana to glioblastoma: Solving problems with science , article Date: Jan 20, 2026 - -
Article Item
-
Article Item
-
Article ItemFralin Biomedical Research Institute scientist to co-chair international forum on gap junctions , article
Co-chairs James Smyth and Silvia Penuela are bringing scientists from across the globe to Arlington to share findings in a rapidly developing field whose insights point to novel therapeutic opportunities in a wide range of disorders and complex diseases.
Date: May 24, 2024 - -
Article ItemFralin Biomedical Research Institute at VTC and Virginia Tech shine as innovations receive TechNite acclaim , article
The Roanoke-Blacksburg Technology Council’s TechNite awards turned a spotlight on translational research taking place at Fralin Biomedical Research Institute at VTC and throughout the region.
Date: May 15, 2024 - -
Article ItemRare Disease Day brings worldwide attention to more than 7,000 rare diseases , article
Virginia Tech research into rare diseases — those that individually affect 200,000 or fewer but collectively touch 1 in 10 people in the U.S. — provides hope in identifying, treating, and supporting patients.
Date: Feb 28, 2024 - -
Article ItemFrom healthy development to cancer treatments, Fralin Biomedical Research Institute scientists aim for impact , article
New Seale Innovation Fund projects fuel a broad spectrum of research focused on cardiovascular disease, diabetes, cancer, stress, brain development, and more.
Date: Jan 29, 2024 - -
Article ItemCommon challenge, different strategies: Virginia Tech Cancer Research Alliance gathers broad mix of researchers and clinicians , article
The second annual Virginia Tech Cancer Research Alliance retreat, hosted this year on the Children’s National Research & Innovation Campus, brought together scientists and physicians on the leading edge of developing innovative therapy types, fresh biological targets, and new technologies to take on cancer.
Date: Jun 21, 2023 - -
Article ItemJoining forces: Virginia Tech Cancer Research Alliance scientists to share ideas, innovations , article
For its second annual retreat, the Virginia Tech Cancer Research Alliance is broadening its reach and opportunities for collaboration and innovation. The 2023 event will take place May 24 and May 25 in Washington, D.C., at the Children’s National Research and Innovation Campus.
Date: May 23, 2023 - -
Article ItemPhilanthropy supports pilot projects to take on health challenges such as heart disease, diabetes, cancer, stress, and chronic pain , article
Giving Day contributions to the Fralin Biomedical Research Institute at VTC have double the impact, unlocking $20,000 to the Seale Innovation Fund to accelerate innovation
Date: Feb 15, 2023 -
Page 1 of 3 | 25 Results
Recent Media Coverage
-
Redirect ItemTech Fixated: Lab-Designed Peptide Targets Glioblastoma Stem Cells , redirect Date: Aug 19, 2025 -
-
Redirect ItemKnowridge: New drug could slow aggressive brain cancer recurrence , redirect Date: Aug 12, 2025 -
-
Redirect ItemTV Europa: New drug could fight deadly brain cancer , redirect Date: Jun 29, 2025 -
-
Redirect Item
-
Redirect Item
-
Redirect Item
-
Redirect Item
-
Redirect Item
-
Redirect Item
-
Redirect Item
Page 1 of 4 | 39 Results